Abstract
Antibodies, obtained from human or animal sera have played a small role in therapy for many years. They are used to neutralise venoms, some bacterial toxins and viral antigens. More recently antilymphocyte globulin has been used as an adjunct to the treatment of allograft rejection. Attempts to use antibodies more widely in vivo have been limited by lack of specificity, by inhomogeneity and variability of preparations and by adverse side-effects, especially associated with the early widespread use of horse serum as a source of antibodies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arnon R. and Sela M., 1982, In vitro and in vivo efficacy of conjugates of daunomycin with anti-tumour antibodies, Immunol Rev., 62: 5.
Burstein S. and Knapp R., 1977, Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates, J. Med. Chem., 20: 950.
Clark M., Cobbold S., Hale G. and Waldmann H., 1983, Advantages of rat monoclonal antibodies, Immunol. Today, 4: 100.
Crawford D.H., Huehns E.R. and Epstein M.A., 1983, Therapeutic use of human monoclonal antibodies, Lancet 1/. 1040.
Epenetos A.A., 1984, Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment, Lancet 1: 1441.
Garnett M.C., Embleton M.J., Jacobs E. and Baldwin R.W., 1983, Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro, Int. J. Cancer 31: 661.
Goldenberg D.M., Sharkey R.M., Primus F.J., Mizusawa E. and Hawthorne M.F., 1984, Neutron-capture therapy of human cancer: In vivo results on tumor localization of boron-10- labelled antibodies to carcinoembroyonic antigen in the GW-39 tumor model system, Proc. Natl. Acad. Sci 81: 560.
Guclu A., Ghose T., Tai J. and Mammen M., 1976, Binding of chlorambucil with antitumor globulins and its effect on drug and antibody activities, Eur J. Cancer 12: 95.
Haber E., 1983. Antibodies as models for rational drug design, Biochem Pharmacol 32: 1967
Herlyn D. and Koprowski H., 1982, IgG2a monoclonal antibodies inhibit human tumour growth through interaction with effector cells, Proc. Natl. Acad. Sci., 79: 4761.
Hugh-Jones N.C., Gorick B.D. and Howard J.C., 1983, The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies, Eur. J. Immunol., 13: 635
Jansen F.K., Blythman H.E., Carriere D., Casellas P., Gros 0. Gros P., Laurent J.C., Paolucci F., Pau B., Poncelet P., Richer G., Vidal H. and Voisin G.A., 1982, Immunotoxins: hybrid molecules combining high specifity and potent cytotoxicity, Immunol Rev. 62: 185.
Kulkarni P.N., Blair A.H. and Ghose T.I., 1981, Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumour growth in vivo, Cancer Res. 41: 2700
Latif Z.A., Lozzio B.B., Wust C.J., 1980, Evaluation of drug- antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice, Cancer, 45: 1326.
Moolten F.L., Schreiber B.M. and Zajdel S.H., 1982, Antibodies conjugated to potent cytotoxins as specific antitumour agents, Immunol Rev., 62: 47.
Miller R.A., Maloney D.G., Warnke R. and Levy R., 1982. Treatment of B cell lymphoma with monoclonal anti-idiotype antibody, N. Engl. J. Med., 306: 517.
Rowland G.F., 1983, Use of antibodies to target drugs to tumour cells, Clinics in Immunol and Allergy, 3: 235.
Rowland G.F., Simmonds R.G., Corvalan J.R.F., Baldwin R.W., Brown J.P., Embleton M.J., Ford C.H.J., Hellstrom K.E., Hellstrom I., Kemshead J.T., Newman C.F. and Woodhouse, C.S., 1983, Monoclonal antibodies for targeted therapy with vindesine. Protides of the Biol. Fluids, 30: 375.
Rowland G.F., Corvalan J.R.F., Axton C.A., Gore V.A., Marsden C.H., Smith W. and Simmonds R.G., 1984. Suppression of growth of a human colorectal tumour in nude mice by vindesine monoclonal anti-CEA conjugates, Protides of the Biol Fluids, 31: 783.
Sears H.F., Herlyn D., Steplewski Z. and Koprowski H., 1984. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma, J. Biol. Resp. Modifiers, 3: 138.
Streem S.B., Novick A.C., Braun W.E. and Steinmuller D., 1983. Antilymphocyte and antithymocyte globulines, Transplant. Proc. 15: 590.
Takahashi H., Terasaki P.I., Kinukawa T., Chia D., Miura K., Okazaki H., Iwaki Y., Taguchi Y., Hardiwidjaja S., Ishizaki M. and Billing R., 1983, Reversal of transplant rejection by antiblast antibody, Lancet II: 1155.
Thorpe P.E. and Ross W.C.J., 1982, The preparation and cytotoxic properties of antibody-toxin conjugates, Immunol. Rev, 62: 119.
Vitetta E.S., Cushley W. and Uhr J.W., 1983, Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells, Proc. Natl. Acad. Sci., 80: 6332.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Rowland, G.F. (1985). Monoclonal Antibodies as Therapeutic Tools In Vivo. In: Klaus, G.G.B. (eds) Microenvironments in the Lymphoid System. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2463-8_94
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2463-8_94
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9495-5
Online ISBN: 978-1-4613-2463-8
eBook Packages: Springer Book Archive